argenx SE
Netherlands · NL0010832176 · reports in USD · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue +90% in the year to Dec 31, 2025, on the year before.
- Return on equity
- It earned 18% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 84% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in USD.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | $445M | $1.2B | $2.2B | $4.2B |
| Operating profit | −$720M | −$425M | −$22M | $1.1B |
| Net profit to shareholders | −$710M | −$295M | $833M | $1.3B |
| Earnings per share | −$13.05 | −$5.16 | $13.92 | $21.08 |
| Cash from operations | −$863M | −$420M | −$83M | $685M |
| Capital spending | $837,000 | $812,000 | $2M | $6M |
| Cash | $801M | $2.0B | $1.5B | $3.5B |
| Total assets | $3.1B | $4.5B | $6.2B | $8.7B |
| Equity | $2.8B | $4.1B | $5.5B | $7.3B |
What they do
In the company's own words, from the annual report.
At argenx, we are defining the future of immunology with an entrepreneurial mindset, bringing together agility, focus, and a collaboration in all that we do. We are a global, commercial-stage, entrepreneurial science company. Our co-creative discovery engine, the Immunology Innovation Program, is powered by partnerships between leading disease biologists and our antibody engineers, enabling us to advance with urgency a robust pipeline of differentiated therapies for severe diseases. We are committed to accelerating innovation, breaking down barriers to access, and building lasting trust through transparency and evidence. Our dynamic pipeline and evidence-driven approach position argenx to deliver sustainable growth and long-term value for patients, healthcare providers, and investors alike. We developed and commercialized the first approved FcRn blocker and we are evaluating efgartigimod
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.